AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04307004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home blood pressure monitoring
Description: Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
Study NCT05400434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Description: PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
Study NCT05400434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Helpers (NH)
Description: Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
Study NCT01753687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ocular scattering of the tear film
Study NCT01753687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optical Coherence Tomography (OCT)
Description: Tear film thickness as measured with OCT
Study NCT01753687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of tear film osmolarity
Study NCT04745611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: 3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
Study NCT02295592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSTstarr+
Description: TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation .
Study NCT02295592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPH
Description: PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
Study NCT04745611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
Study NCT04745611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires Patient
Description: EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) \& Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
Study NCT04745611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires Family
Description: EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
Study NCT02020538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-chloride perioperative intravenous fluid strategy
Description: The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
Study NCT03175133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercise
Description: Strengthening exercises performed with physical therapist.
Study NCT02020538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-chloride perioperative intravenous fluid strategy
Study NCT01839214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-201 160mg
Study NCT01839214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 160mg
Study NCT01839214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00908154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets to match GSK1014802
Study NCT00908154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Sodium channel blocker
Study NCT03728972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IVPB every 3 weeks
Study NCT02243605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT02243605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00998608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: risperidone 4mg/d
Study NCT03328299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
Study NCT03328299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: 20 ml of 0.5 % bupivacaine
Study NCT02676375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Bupropion + NRTs
Study NCT02676375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Treatment
Study NCT02676375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Visits & Calls
Study NCT02676375 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Monotherapy
Study NCT00508430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral
Study NCT00267969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
Study NCT00508430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03842995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Genetic Counselor
Description: Standard of Care
Study NCT03842995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained Healthcare Provider
Description: Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
Study NCT05261152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
Study NCT05261152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
Study NCT00907829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: comparison of the effect of the drug to help improve finger function
Study NCT00907829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle stimulator
Description: comparison of the effect of stimulated muscle(s) on finger function
Study NCT03548740 — intervention group
Intervention type: BIOLOGICAL
Intervention: Human Papillomavirus
Description: women with high-risk Human Papillomavirus or not
Study NCT04421781 — intervention group
Intervention type: OTHER
Intervention: Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT
Description: Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
Study NCT01309633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Sunitinib alternating with Cisplatin and Gemcitabine
Description: Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
Study NCT01309633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
Description: Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
Study NCT01716429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Vegan dietary approaches for weight loss
Study NCT01716429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Reduced calorie diet for weight loss
Study NCT01437748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: Dry powder, 300 mcg, only one inhalation with 24 hours duration
Study NCT01437748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide
Description: Dry powder, 18 mcg, only one inhalation with 24 hours duration
Study NCT00413387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate plus formoterol fumarate combination
Description: 100mcg beclomethasone diproprionate plus 6 mcg formoterol
Study NCT00413387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide plus formoterol combination
Description: 200mcg budesonide plus 6 mcg formoterol
Study NCT02316795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Study NCT02316795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goggle-based device with light-emitting diodes (LED)
Study NCT02316795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocynanine Green
Description: This is a infrared fluorescence imaging contrast agent
Study NCT03998787 — intervention group
Intervention type: OTHER
Intervention: Neurophysiological assessment
Description: Kinematic analysis of movement and transcranial magnetic stimulation
Study NCT02846623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT00267969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
Study NCT02846623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02846623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT02846623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 4 placebo oral capsules
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 4 placebo oral capsules
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 720 mg
Description: Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AV-101 720 mg
Description: Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 1440 mg
Description: Single dose of 4 360 mg AV-101 oral capsules
Study NCT03583554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AV-101 1440 mg
Description: Single dose of 4 360 mg AV-101 oral capsules
Study NCT03934398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Assessments
Description: Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
Study NCT03934398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
Study NCT03934398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessments
Description: Participants will provide blood and urine samples for laboratory assessments.
Study NCT03934398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional/Behavioral Assessments
Description: Participants and parents will fill out questionnaires for emotional/behavioral assessments
Study NCT00226239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
Study NCT00226239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
Study NCT00226239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
Study NCT00226239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies>6 MV may be utilized when appropriate to boost target localized centrally.
Study NCT02808624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-CARNOSINE
Description: L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
Study NCT06535048 — intervention group
Intervention type: DRUG
Intervention: Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
Description: Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks.
Study NCT01800968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Active Drug
Study NCT01800968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01725828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using the Ultrasound to determine the location of the CTM.
Study NCT01725828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Palpation
Description: Using External Palpation to identify cricothyoid membrane
Study NCT00054431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00054431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00054431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02937168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab will be administered as per the dose and schedule specified in the arm.
Study NCT02937168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18 (FDG)
Description: FDG will be administered by IV infusion prior to each PET/CT scan.
Study NCT02937168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludeoxyglucose F 18 (FDG)
Description: FDG will be administered by IV infusion prior to each PET/CT scan.
Study NCT02937168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
Study NCT02543034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Betafoam Wound Dressing
Description: Foam dressing including Betadine iodine
Study NCT04283149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVO/EVO+ Visian ICL
Description: The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Study NCT02543034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum Gauze
Description: Gauze dressing
Study NCT02543034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Wound Dressing
Description: Foam dressing
Study NCT04217681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
Study NCT04217681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music/self-care
Description: It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
Study NCT04217681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care motivation
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
Study NCT04217681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care malignant pain
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
Study NCT01506193 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTetra™
Description: One dose administered subcutaneously
Study NCT03080064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach Intervention
Description: Please see arm description.
Study NCT03191461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine stress test MRI
Description: Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane